Table 2 Pathological findings of patients with SEC who underwent ESD followed by CRT
Patient | Age | Sex | T Stage | ly | v | INF C | DI | HM | VM | Months to disease recurrence (site) |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 69 | Male | T1b-SM2 | (+) | (−) | (−) | (−) | (−) | (−) | (−) |
2 | 78 | Male | T1b-SM2 | (−) | (−) | (−) | (−) | (−) | (+) | (−) |
3 | 60 | Male | T1b-SM3 | (+) | (−) | (−) | (+) | (+) | (−) | 24 (paraaortic lymph node) |
4 | 80 | Male | T1b-SM2 | (−) | (−) | (−) | (−) | (−) | (−) | (−) |
5 | 55 | Male | T1a-MM | (+) | (−) | (−) | (+) | (−) | (−) | (−) |
6 | 73 | Male | T1b-SM1 | (−) | (+) | (+) | (+) | (−) | (−) | (−) |
7 | 65 | Male | T1b-SM2 | (+) | (−) | (−) | (+) | (−) | (−) | (−) |
8 | 74 | Female | T1a-MM | (+) | (+) | (−) | (+) | (−) | (−) | (−) |
9 | 68 | Male | T1b-SM1 | (+) | (−) | (−) | (+) | (−) | (−) | (−) |
10 | 68 | Female | T1b-SM2 | (+) | (−) | (−) | (+) | (−) | (−) | (−) |
11 | 71 | Male | T1a-MM | (+) | (−) | (−) | (+) | (−) | (−) | (−) |
12 | 80 | Male | T1b-SM1 | (+) | (−) | (−) | (+) | (+) | (−) | (−) |
13 | 50 | Male | T1b-SM2 | (−) | (−) | (−) | (−) | (−) | (−) | (−) |
14 | 76 | Female | T1b-SM2 | (+) | (+) | (−) | (−) | (−) | (+) | (−) |
15 | 68 | Male | T1b-SM1 | (−) | (−) | (−) | (+) | (+) | (−) | (−) |
16 | 60 | Male | T1a-MM | (+) | (−) | (−) | (+) | (−) | (−) | (−) |